Research programme: specific immunotherapy vaccines - TheVax

Drug Profile

Research programme: specific immunotherapy vaccines - TheVax

Alternative Names: HPV16/18 Bivalent; Specific ImmunoTherapy - TheVax; TVGV-2; TVGV-HB; TVGV-HC; TVGV-LC

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheVax
  • Class Antineoplastics; Antivirals; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical cancer; Hepatitis B; Liver cancer; Lung cancer
  • Research Hepatitis C

Most Recent Events

  • 20 Oct 2017 Pharmacodynamics and safety data from a preclinical trial in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 04 Nov 2016 Preclinical trials in Liver cancer in USA (Parenteral) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top